Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand

Seong Ju Na, Su Young Chae, Seulki Lee, Kyeongsoon Park, Kwang Meyung Kim, Jae Hyung Park, Ick Chan Kwon, Seo Young Jeong, Kang Choon Lee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has gained much attention due to its potent therapeutic effect for cancer and rheumatoid arthritis. In this study, we attempted to develop the injectable formulations which can stabilize TRAIL and thus show prolonged blood circulation in vivo. The positively charged TRAIL was mixed with hyaluronic acid (HA), resulting in the formation of nanocomplexes. The zeta-potentials of nanocomplexes and their mean diameters were significantly dependent on the feed ratio of HA to TRAIL. The increase in the feed ratio of HA reduced the particle size and decreased the value of the zeta-potential. The bioactivity of TRAIL in the complexes was comparable to that of native TRAIL, indicating that the complex formation did not affect the activity of TRAIL. Furthermore, the stability of TRAIL in the complexes was retained for 6 days, during which the bioactivity of native TRAIL disappeared. When native TRAIL was subcutaneously injected into the rats, its plasma concentration was not detectable after 12 h. In contrast, for HA/TRAIL nanocomplexes in 1% HA solution, substantial amount of TRAIL was circulated in blood for up to 5 days. These results imply that HA-based formulations of TRAIL hold the potential as the therapeutics.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume363
Issue number1-2
DOIs
Publication statusPublished - 2008 Nov 3
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Hyaluronic Acid
Blood Circulation
Therapeutic Uses
Particle Size
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Injections

Keywords

  • Hyaluronic acid
  • Nanocomplex
  • Protein stability
  • TRAIL

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. / Na, Seong Ju; Chae, Su Young; Lee, Seulki; Park, Kyeongsoon; Kim, Kwang Meyung; Park, Jae Hyung; Kwon, Ick Chan; Jeong, Seo Young; Lee, Kang Choon.

In: International Journal of Pharmaceutics, Vol. 363, No. 1-2, 03.11.2008, p. 149-154.

Research output: Contribution to journalArticle

Na, SJ, Chae, SY, Lee, S, Park, K, Kim, KM, Park, JH, Kwon, IC, Jeong, SY & Lee, KC 2008, 'Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand', International Journal of Pharmaceutics, vol. 363, no. 1-2, pp. 149-154. https://doi.org/10.1016/j.ijpharm.2008.07.013
Na, Seong Ju ; Chae, Su Young ; Lee, Seulki ; Park, Kyeongsoon ; Kim, Kwang Meyung ; Park, Jae Hyung ; Kwon, Ick Chan ; Jeong, Seo Young ; Lee, Kang Choon. / Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. In: International Journal of Pharmaceutics. 2008 ; Vol. 363, No. 1-2. pp. 149-154.
@article{03da9fd82b274fd4976f4b2d5ac11d6c,
title = "Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand",
abstract = "The tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has gained much attention due to its potent therapeutic effect for cancer and rheumatoid arthritis. In this study, we attempted to develop the injectable formulations which can stabilize TRAIL and thus show prolonged blood circulation in vivo. The positively charged TRAIL was mixed with hyaluronic acid (HA), resulting in the formation of nanocomplexes. The zeta-potentials of nanocomplexes and their mean diameters were significantly dependent on the feed ratio of HA to TRAIL. The increase in the feed ratio of HA reduced the particle size and decreased the value of the zeta-potential. The bioactivity of TRAIL in the complexes was comparable to that of native TRAIL, indicating that the complex formation did not affect the activity of TRAIL. Furthermore, the stability of TRAIL in the complexes was retained for 6 days, during which the bioactivity of native TRAIL disappeared. When native TRAIL was subcutaneously injected into the rats, its plasma concentration was not detectable after 12 h. In contrast, for HA/TRAIL nanocomplexes in 1{\%} HA solution, substantial amount of TRAIL was circulated in blood for up to 5 days. These results imply that HA-based formulations of TRAIL hold the potential as the therapeutics.",
keywords = "Hyaluronic acid, Nanocomplex, Protein stability, TRAIL",
author = "Na, {Seong Ju} and Chae, {Su Young} and Seulki Lee and Kyeongsoon Park and Kim, {Kwang Meyung} and Park, {Jae Hyung} and Kwon, {Ick Chan} and Jeong, {Seo Young} and Lee, {Kang Choon}",
year = "2008",
month = "11",
day = "3",
doi = "10.1016/j.ijpharm.2008.07.013",
language = "English",
volume = "363",
pages = "149--154",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand

AU - Na, Seong Ju

AU - Chae, Su Young

AU - Lee, Seulki

AU - Park, Kyeongsoon

AU - Kim, Kwang Meyung

AU - Park, Jae Hyung

AU - Kwon, Ick Chan

AU - Jeong, Seo Young

AU - Lee, Kang Choon

PY - 2008/11/3

Y1 - 2008/11/3

N2 - The tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has gained much attention due to its potent therapeutic effect for cancer and rheumatoid arthritis. In this study, we attempted to develop the injectable formulations which can stabilize TRAIL and thus show prolonged blood circulation in vivo. The positively charged TRAIL was mixed with hyaluronic acid (HA), resulting in the formation of nanocomplexes. The zeta-potentials of nanocomplexes and their mean diameters were significantly dependent on the feed ratio of HA to TRAIL. The increase in the feed ratio of HA reduced the particle size and decreased the value of the zeta-potential. The bioactivity of TRAIL in the complexes was comparable to that of native TRAIL, indicating that the complex formation did not affect the activity of TRAIL. Furthermore, the stability of TRAIL in the complexes was retained for 6 days, during which the bioactivity of native TRAIL disappeared. When native TRAIL was subcutaneously injected into the rats, its plasma concentration was not detectable after 12 h. In contrast, for HA/TRAIL nanocomplexes in 1% HA solution, substantial amount of TRAIL was circulated in blood for up to 5 days. These results imply that HA-based formulations of TRAIL hold the potential as the therapeutics.

AB - The tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has gained much attention due to its potent therapeutic effect for cancer and rheumatoid arthritis. In this study, we attempted to develop the injectable formulations which can stabilize TRAIL and thus show prolonged blood circulation in vivo. The positively charged TRAIL was mixed with hyaluronic acid (HA), resulting in the formation of nanocomplexes. The zeta-potentials of nanocomplexes and their mean diameters were significantly dependent on the feed ratio of HA to TRAIL. The increase in the feed ratio of HA reduced the particle size and decreased the value of the zeta-potential. The bioactivity of TRAIL in the complexes was comparable to that of native TRAIL, indicating that the complex formation did not affect the activity of TRAIL. Furthermore, the stability of TRAIL in the complexes was retained for 6 days, during which the bioactivity of native TRAIL disappeared. When native TRAIL was subcutaneously injected into the rats, its plasma concentration was not detectable after 12 h. In contrast, for HA/TRAIL nanocomplexes in 1% HA solution, substantial amount of TRAIL was circulated in blood for up to 5 days. These results imply that HA-based formulations of TRAIL hold the potential as the therapeutics.

KW - Hyaluronic acid

KW - Nanocomplex

KW - Protein stability

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=51649117750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649117750&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2008.07.013

DO - 10.1016/j.ijpharm.2008.07.013

M3 - Article

C2 - 18694811

AN - SCOPUS:51649117750

VL - 363

SP - 149

EP - 154

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -